A novel FlashPlate scintillation proximity assay has been developed for the high-throughput screening (HTS) of large compound libraries to identify inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1), an important enzyme involved in DNA repair. The assay was originally developed for the 96-well FlashPlate but is easily transferred to a 384-well format. Moreover, the authors demonstrate that the assay is sufficiently sensitive to determine accurate IC 50 values and adaptable for kinetic evaluation of lead molecules. The mechanism of action of the assay requires the binding of PARP-1 to a double-stranded DNA oligonucleotide leading to the active enzyme. Using NAD + and 3 H-NAD + as substrate, activated PARP-1 synthesizes labeled poly(ADP-ribose) chains. Once the reaction is stopped, ADP-ribose polymers are brought into proximity with the pretreated FlashPlate walls, resulting in signal amplification. This signal is then detected by a TopCount scintillation plate reader. The developed assay is a robust and reproducible method of screening for PARP-1 inhibitors that is low maintenance and costeffective and can easily be automated. (Journal of Biomolecular Screening 2003:347-352) 
INTRODUCTION
P OLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1) plays a pivotal role in the repair of nuclear DNA damage through the base excision repair (BER) pathway. 1 It is an abundant enzyme found in the nuclei of most eukaryotic cells. PARP-1 is activated rapidly following DNA damage caused either by exogenous factors (i.e., genotoxic agents, including certain chemotherapies and ionizing radiation [IR]) or endogenous sources such as oxygen radicals produced via cellular metabolism. 2 The 113 KDa protein binds to the DNA at the site of the DNA lesion (i.e., DNA single-or doublestrand breaks) and, using NAD + as its substrate, synthesizes polymers of ADP-ribose. 3, 4 These branched polymers can often comprise more than 200 subunits of ADP-ribose and are transferred to primarily PARP-1 itself and a variety of other acceptor proteins, including histones, DNA-polymerases, and topoisomerase I and II in vitro. 5 This immediate response to DNA damage is believed to play an important role in the signaling to other enzymes involved in the BER pathway and in the maintenance of genomic integrity as a whole. 6 Inhibition of PARP-1 activity in certain tumor cell lines results in these cells becoming far more susceptible to the action of certain chemotherapeutic agents and IR. 7, 8 Moreover, PARP-1 has been implicated in cellular necrosis following high levels of DNA damage. The utilization of NAD + and subsequent adenosine triphosphate (ATP) energy store depletion following massive PARP-1 activation leads to cell death by a necrotic mechanism. 9 Thus, PARP-1 inhibition is proposed to have therapeutic potential not only in oncology but in disease states in which high levels of DNA damage can occur such as stroke, ischemia, and reperfusion injury. 2, 10 The aim of the present study was to develop a high-throughput screening (HTS) assay capable of screening large libraries of compounds to identify inhibitors of the PARP-1 enzyme. Furthermore, the assay had to be adaptable so that the same assay format could be used to accurately calculate IC 50 and Ki values of identified inhibitors.
The requirements of the assay were throughput, homogeneity (minimal steps), reproducibility, low cost, accuracy, and the ability to be automated. The assay described below incorporates all these factors into a FlashPlate scintillation proximity assay (SPA) format. We also report that the developed assay is easily transferable from the 96-well to the 384-well plate format.
MATERIALS AND METHODS

Reagents
The 96-and 384-well FlashPlates were supplied by PerkinElmer (formerly NEN). NAD + (free acid) was supplied by Boehringer Manheim. 3 H-NAD + (specific activity: 0.1 µCi/µL) was supplied by PerkinElmer. Complementary oligonucleotides were purchased from MWG Biotech: 5′-ACT TGA TTA GTT ACG TAA CGT TAT GAT TGA-3′ for M3 and 5′-TCA ATC ATA ACG TTA CGT AAC TAA TCA AGT-3′ for M5. Scintillation cocktail was from Packard Bioscience (now PerkinElmer). SPsepharose fast flow was obtained from Amersham Biosciences, and DNA-cellulose and NP-40 (IGEPAL,CA-630) were purchased from Sigma.
Purification of PARP-1 from HeLa nuclear extract
All purification steps were performed at 4°C. HeLa nuclear extract (50 mL; Computer Cell Culture Centre, Mons, Belgium) was diluted 1:1 with ice-cold buffer (buffer A: 10% (v/v) glycerol, 25 mM HEPES, 2 mM MgCl 2 , 1 mM EDTA, 1 mM DTT, pH 7.4), and the sample was centrifuged at 10,000 rpm for 20 min. Cleared supernatant was applied to an SP-sepharose fast-flow column (100 mL column volume) previously equilibrated in buffer A containing 100 mM KCl. The bound protein was eluted using a continuous salt gradient of buffer A containing 100 to 500 mM KCl over 10 column volumes. PARP-1 protein was found to elute from the SPsepharose between 300 and 400 mM KCl (as determined by Western blot analysis). Fractions containing PARP-1 were then pooled and applied to a DNA-cellulose column (~4 mL column volume; 1.5 × 2.5 cm) equilibrated in buffer A (250 mM KCl). Protein was batch-eluted with buffer A containing 500 mM KCl, followed by buffer A containing 1 M KCl. Pure PARP-1 was found to elute in buffer A with 1 M KCl, as judged by silver stain analysis of 7% SDS-PAGE gels. Fractions containing PARP-1 were pooled, aliquoted, and stored at -80°C. PARP-1 protein was found to be stable for up to 6 months under these storage conditions. The concentration of PARP-1 was in the order of 50 ng/µL when purified in the above manner.
Precoating of FlashPlates
FlashPlates were taken from storage at 4°C. Then, 200 µL (96well) or 90 µL (384-well) coating buffer (coating buffer: 0.015 M sodium carbonate, 0.035 M sodium bicarbonate, pH 9.6) was added to each well, and the plates were shaken at room temperature (RT) for 1 h and the buffer discarded. Plates not used immediately could be stored dry at -20°C for up to 2 weeks with no loss of binding capacity.
FlashPlate assay (96-well screening assay)
To columns 1 through 10, 1 µL of compound (in DMSO) was added, and 1 µL DMSO only was added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 was diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl 2 , 50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 µL added to all 96 wells (final PARP-1 concentration in the assay was~1 ng/ µL). The plate was sealed and shaken at RT for 15 min. Following this, 10 µL of positive reaction mix (0.2 ng/µL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 µM of NAD + final assay concentration, and 0.075 µCi 3 H-NAD + per well) was added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, was added to column 12 (with the mean negative control value used as the background). The plate was resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 µL of ice-cold acetic acid (30%) was added to each well to stop the reaction, and the plate was sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate was then determined in counts per minute (CPM) using the TopCount (Packard) plate reader.
FlashPlate assay (384-well screening assay)
The assay for the 384-well plate was carried out under essentially the same assay conditions described above. Final PARP-1 concentration was 2 ng/µL in a final volume of 20 µL per well. Positive and negative reaction mixes were prepared to the same final concentrations as for the 96-well assay, with 3 H-NAD + maintained at 0.075 µCi per well, and 10 µL was added to each reaction. Then, 30 µL of ice-cold 30% acetic acid was added to stop the reaction.
Determination of inhibitor kinetics
The kinetic experiments were set up using the 96-well FlashPlate format. Competitive curves were determined using 5 final concentrations of NAD + (250, 50, 10, 5, and 1 µM) and at 5 different concentrations of inhibitor (in a range surrounding the predetermined IC 50 value). All other parameters remained the same as in the 96-well screening assay (except for the increase of 3 H-NAD + to 0.15 µCi per well). To estimate total 3 H levels in the assay (see equation below), duplicate 2 µL aliquots were transferred at the initiation of the reaction from positive control wells to a 96-well opaque plate. Then, 50 µL scintillation fluid was added and the CPM measured using the TopCount. However, this cannot be seen as an accurate method of establishing total 3 H levels as differences between scintillant-and FlashPlate-counting efficiencies may occur. Nevertheless, sufficient information is produced to construct a Lineweaver-Burk plot from 1/V values and 1/NAD + concentrations. IC 50 experiments were performed with duplicates on each plate (n = 2) on 3 separate occasions, and the values were determined from a 1-phase exponential decay slope fitted using Prism (GraphPad Software, Inc.). For the calculation of the coefficient of variance (CV) of positive-and negative-well CPMs, the following equation was used:
where SD is the standard deviation of the CPMs.
The calculation of the Z factor was performed according to the following equation 11 :
where SD is the standard deviation of positive (POS) or negative (NEG) controls. The calculation of V for kinetic experiments was established from duplicate points for each NAD + and inhibitor concentration, and the values were put into the following equation:
where CPM1 is the mean of CPMs for the duplicate wells at a certain NAD + and inhibitor concentration, CPM2 × 25 represents the calculated total 3 H-NAD + in the reaction (from the 2-µL aliquot), S is the concentration of substrate (NAD + ) in pmol, T is the time of the reaction incubation, and E is the concentration of enzyme (PARP-1). V is expressed as pmol NAD + transferred into product per minute per pmol of PARP-1.
RESULTS AND DISCUSSION
PARP-1 FlashPlate method
Various assay methods have been described for the identification of inhibitors to the nuclear enzyme PARP-1. Most of these methods on the whole are not adaptable for HTS or are too timeconsuming for extensive screening programs. With this in mind, we opted to develop a new and easy-to-use screening assay to identify novel PARP-1 inhibitors. To this end, a FlashPlate proximity assay was developed that proved to be a reliable, fast, cost-effective, reproducible, and robust method for manual as well as automated screening.
The principles of the assay are as follows. Following the preincubation of PARP-1 with compound, the reagents (DNA, NAD + , and 3 H-NAD + ) are added to the wells to initiate the reaction. PARP-1 then binds to the double-stranded oligonucleotide DNA and becomes activated. Using NAD + as its substrate, PARP-1 will synthesize poly-ADP ribose chains in an automodification fashion. These polymers will incorporate 3 H-adenine from the labeled NAD + into their structures. Upon termination of the reaction, the PARP-1-ADP-ribose complex comes into close proximity with the scintillant-coated FlashPlate walls, leading to signal amplification. It was important to pretreat the FlashPlates because a greatly reduced signal was observed when the wells were not pretreated.
Other assay methods have used SDS-PAGE followed by autoradiography to determine incorporation of the radiolabeled polymers onto PARP. This assay format has very low throughput and, for optimal assay sensitivity, requires the use of 32 P, which is a more hazardous isotope to use than tritium. More sophisticated ELISA assays have been developed, 12 but these involve transfers and frequent washing steps, making them labor intensive and difficult to automate. One of the main advantages of our assay is that it is reasonably homogeneous, requiring minimum human intervention, therefore allowing it to be adapted onto screening platforms for HTS. A recent SPA assay format for the identification of PARP inhibitors (SPA Amersham Pharmacia Biotech) has been described for 96-well plates by Cheung and Zhang. 13 Although our method is reasonably similar, it does not require the use of tagged substrates and is potentially more cost-effective in the initial setup phase in comparison to the SPA technology.
Plate validation
Both the 96-well and the 384-well FlashPlate assays were designed for the screening of large compound libraries. To produce reliable screening data, the assay needed to be robust and show good reproducibility between wells and plates. CVs and the Z factor across plates performed using a semiautomated format identified this as a reliable method under stringent assay conditions. Figure 1a shows the mean of CPMs from a representative 96well plate performed under screening conditions. The plate comprises columns of positive control wells and negative controls. The mean CV across the plate was determined at 8.6% for positive CPMs and 15% for negative CPMs. Consistently, the negative results produced slightly higher values, principally due to the very low counts. The positive-to-negative ratios for the plates were established in the region of 15:1, making the assay sufficiently sensitive for identifying inhibitors. The Z factor for this plate was calculated as 0.68, which indicates an "excellent" assay, as determined by Zhang et al. 11 A good signal was maintained, indicating that the binding to the surface of the FlashPlate was stable. Generally, the plates were counted 1 h after addition of acetic acid, but if the plate was left standing for longer periods of time (> 12 h), there was only a small increase in positive CPM seen (around 8% increase for a plate left overnight) but a larger increase in negative CPM (25% overnight). Acetic acid was used principally to stop the PARP-1 reaction continuing over the final binding period. However, the addition of acetic acid was observed to have no effect on the binding properties as experiments substituting acetic acid for buffer B indicated no loss of signal. It is also presumed that all incorporated tritium (into the ADP-ribose chains) is bound to the wall of the reaction well because transfer of the reaction mixture, following the full incubation period, into a further well (with an hour's further incubation) produced no signal. However, the original well, previously containing the reaction mixture, still produced a full signal.
IC 50 values of known PARP-1 inhibitors
It was important to check, prior to screening, the sensitivity of the assay and its performance as measured against known PARP-1 inhibitors. In this respect, a number of commercially available PARP-1 inhibitors were purchased and their IC 50 s determined using the 96-well format. The results were compared with published values ( Table 1 ). The data showed that the IC 50 values obtained were comparative with those results quoted for the commercially available inhibitors. The level of NAD + used in the assay was 5 µM, and small variations noted in IC 50 may be due to differences in the substrate concentrations between our assay and those reported for the commercially available inhibitors.
384-well assay development
Although the 96-well plate assay was both easy to use and a robust means of screening, there was a need for greater screening capacity. To increase the throughput of the assay and reduce consumable costs, the 384-well FlashPlate assay was developed. The transfer of the assay from a 96-to 384-well format was not merely a case of reducing the assay volume. We found that it was necessary to keep the amount of the activity marker the same as for the 96-well plate (i.e., 0.075 µCi per well for 3 H-NAD + ), despite the volume being reduced to 30 µL. Under these conditions, the assay showed similar results in terms of its reproducibility to that of the 96-well plate format. In exploratory experiments, the CPM values ( Fig. 1b ) across the positive controls (up to column 20) and negative controls (background, remaining columns) were very reproducible, in which the percentage CV was 10% for positive wells and around 24% for negative wells. The positive-to-negative ratio was 20:1. Similarly, to the 96-well plate assay, a Z factor of 0.62 was calculated for this control plate, again indicating an "excellent" assay. 11 To fully evaluate the 384-well assay as a real alternative to the 96-well plate, a number of inhibitors identified through screening were tested in both assay formats and IC 50 values compared. Figure  2a ,b shows comparative IC 50 plots for 2 potent PARP-1 inhibitors, KU-56183 and KU-56186, in the 96-and 384-well assay formats, respectively (see also Table 2 ). Although there were slight variations between the results for the 96-and 384-well IC 50 s, the general ranking of compounds in terms of their potency was in the same order. This demonstrates that the proximity assay is fully transferable to the 384-well format using the FlashPlate methodology.
Kinetic data
Most PARP-1 inhibitors to date have been designed based on the structure of the nicotinamide moiety of NAD and, as such, are competitive for the binding of NAD. 15, 16 To investigate the binding properties of KuDOS PARP-1 inhibitors, identified through inhouse screening, the FlashPlate methodology was adapted to investigate the mode of inhibition. Using a commercially available known competitive inhibitor, the modified phenanthridinone PJ34 17 , examination of the Lineweaver-Burk plot (Fig. 3 ) did indeed demonstrate the competitive behavior of this compound against NAD + . Although this method may not give a truly accurate calculated velocity, due to the differences in counting efficiencies between FlashPlate and scintillation, it was still sufficient to determine the competitive nature of novel PARP-1 inhibitors.
CONCLUSIONS
In this study, we have shown a robust and reproducible method for the screening for PARP-1 inhibitors. This method is simple enough to be used for other polymer-synthesizing enzymes, of which there are several members identified within the PARP family, including tankyrase and vault PARP. The adaptation to the 384well FlashPlate assay means that HTS of large libraries is possible with minimal costs. 
